KALVISTA PHARMACEUTICALS INC's ticker is KALV and the CUSIP is 483497103. A total of 69 filers reported holding KALVISTA PHARMACEUTICALS INC in Q1 2019. The put-call ratio across all filers is - and the average weighting 1.2%.
Quarter-by-quarter ownership
Value | Shares | Weighting | ||||
---|---|---|---|---|---|---|
Q3 2023 | $665 | -48.3% | 69,100 | -51.7% | 0.00% | -50.0% |
Q2 2023 | $1,286 | +102.8% | 142,928 | +77.3% | 0.00% | +100.0% |
Q1 2023 | $634 | -0.5% | 80,600 | -14.5% | 0.00% | 0.0% |
Q4 2022 | $637 | -100.0% | 94,300 | -24.0% | 0.00% | -66.7% |
Q3 2022 | $1,801,000 | -20.2% | 124,100 | -45.9% | 0.00% | 0.0% |
Q2 2022 | $2,257,000 | +810.1% | 229,370 | +1265.3% | 0.00% | – |
Q1 2022 | $248,000 | -16.5% | 16,800 | -25.1% | 0.00% | – |
Q4 2021 | $297,000 | -27.7% | 22,427 | -4.7% | 0.00% | -100.0% |
Q3 2021 | $411,000 | -89.6% | 23,528 | -84.7% | 0.00% | -80.0% |
Q1 2021 | $3,942,000 | +319.8% | 153,428 | +210.4% | 0.01% | +400.0% |
Q4 2020 | $939,000 | +87.8% | 49,428 | +19.5% | 0.00% | – |
Q2 2020 | $500,000 | +37.4% | 41,346 | -13.0% | 0.00% | – |
Q1 2020 | $364,000 | +64.7% | 47,528 | +149.8% | 0.00% | – |
Q3 2019 | $221,000 | -95.2% | 19,028 | -88.1% | 0.00% | -100.0% |
Q1 2019 | $4,577,000 | +29.3% | 159,929 | -10.8% | 0.00% | 0.0% |
Q4 2018 | $3,540,000 | +36.4% | 179,229 | +52.7% | 0.00% | +33.3% |
Q3 2018 | $2,595,000 | +269.7% | 117,349 | +48.3% | 0.00% | – |
Q2 2018 | $702,000 | +70.4% | 79,156 | +82.3% | 0.00% | – |
Q1 2018 | $412,000 | -52.4% | 43,428 | -51.1% | 0.00% | -100.0% |
Q4 2017 | $865,000 | – | 88,728 | – | 0.00% | – |
Download |
Other shareholders
Name | Shares | Value | Weighting ↓ |
---|---|---|---|
Saturn V Capital Management LP | 719,937 | $6,697,459 | 5.56% |
TCG Crossover Management, LLC | 3,395,495 | $22,953,546 | 4.05% |
VR Adviser, LLC | 2,916,667 | $19,716,669 | 3.32% |
TANG CAPITAL MANAGEMENT LLC | 3,196,446 | $21,607,975 | 3.14% |
Prosight Management, LP | 621,667 | $4,202,469 | 2.29% |
Opaleye Management Inc. | 923,200 | $6,240,832 | 2.17% |
GREAT POINT PARTNERS LLC | 1,055,801 | $7,137,215 | 1.40% |
Frazier Life Sciences Management, L.P. | 3,238,859 | $21,894,687 | 1.36% |
DAFNA Capital Management LLC | 616,032 | $4,164,376 | 1.17% |
Vivo Capital, LLC | 856,008 | $5,787 | 0.67% |